Comparison of Sensitivity between Mantoux test, Quantiferon-TB Gold with Bronchoalveolar Lavage for GeneXpert in Renal Transplant for Latent Tuberculosis

Ghulam Mustafa; Nauman Kashif; Ruqaiyya Nazir; Sohail Sabir; Farrukh Islam; Ashfaq Altaf

doi:10.51253/pafmj.v76i3.12764

Authors

Ghulam Mustafa Department of Nephrology, Armed Forces Institute of Urology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Nauman Kashif Department of Nephrology, Armed Forces Institute of Urology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Ruqaiyya Nazir Department of Physiology, Islamic International Medical College, Rawalpindi Pakistan
Sohail Sabir Department of Nephrology, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Farrukh Islam Department of Nephrology, Armed Forces Institute of Urology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Ashfaq Altaf Department of Nephrology, Combined Military Hospital Quetta/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i3.12764

Keywords:

Hemodialysis, Latent Tuberculosis, Renal Transplantation

Abstract

Objectives: To compare the sensitivity of the Mantoux test and QuantiFERON-TB Gold plus assay for diagnosing latent tuberculosis in patients of chronic kidney disease being considered for living renal transplant.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Nephrology, Armed Forces Institute of Urology, Rawalpindi and Pak Emirates Military Hospital, Rawalpindi Pakistan, from Sep 2023 to Jun 2024.

Methodology: The study included 306 patients (of both genders) of chronic kidney disease. Mantoux test and QuantiFERON-TB Gold plus assay were performed. GeneXpert analysis of Broncho alveolar lavage was performed for patients who tested positive either for Mantoux or Quantiferon-TB gold assay to confirm the active tuberculosis. Data was analyzed using SPSS.

Results: In the study, out of 306 patients, 6 were (1.96%) tested positive for the Mantoux test and of those, 2 were also positive for GeneXpert analysis of Bronchoalveolar lavage. On the other hand 9 patients (2.94%) tested positive for the QuantiFERON TB Gold plus assay test, with 3 of them were positive for GeneXpert analysis.

Conclusion: This study highlights the critical need for latent TB diagnosis in patients with chronic kidney disease. It suggests that the Mantoux test is less sensitive as compared to QuantiFERON-TB Gold test in our population so it is not recommended for screening of latent tuberculosis in patients of chronic kidney disease.

Downloads

Download data is not yet available.

References

1. Litvinjenko S, Magwood O, Wu S, Wei X. Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews. Lancet Infec Dis 2023; 23(12): 1395-1407.

https://doi.org/10.1016/S1473-3099(23)00372-9

2. Khan PY, Paracha MS, Grundy C, Madhani F, Saeed S, Maniar L, et al. Insights into tuberculosis burden in Karachi, Pakistan: A concurrent adult tuberculosis prevalence and child Mycobacterium tuberculosis infection survey. PLOS Glob Public Health 2024: 2155-2172.

https://doi.org/10.1371/journal.pgph.0002155

3. Zhang Y, Zhou G, Shi W, Shi W, Hu M, Kong D, et al. Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT. TB and TST: a systematic review and meta-analysis. BMC Infect Dis 2023; 23(1): 40-51.

https://doi.org/10.1186/s12879-023-08008-2

4. Menzies NA, Wolf E, Connors D, Bellerose M, Sbarra AN, Cohen T, et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect Dis 2018; 18(8): e228-e238.

https://doi.org/10.1016/S1473-3099(18)30134-8

5. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children Clin Infect Dis 2017; 62(2): 111-115.

https://doi.org/10.1093/cid/ciw778

6. Kim EY, Lim JE, Jung JY, Son JY, Lee KJ, Yoon YW, et al. Performance of the tuberculin skin test and interferon-γ release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009: 9: 207

https://doi.org/10.1186/1471-2334-9-207

7. Yi L, Sasaki Y, Nagai H, Ishikawa S, Takamori M, Sakashita K, et al. Evaluation of QuantiFERON-TB Gold Plus for detection of Mycobacterium tuberculosis infection in Japan Sci Rep 2016; 6(1): 30617.

https://doi.org/10.1038/srep30617

8. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J 2016; 48(5): 1411-1419. https://doi.org/10.1183/13993003.00510-2016

9. Xu Y, Yang Q, Zhou J, Zhou F, Hezhang Y, Gao Y, et al. Comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold-Plus in the Diagnosis of Mycobacterium tuberculosis Infections in Immunocompromised Patients: a Real-World Study. Microbiol Spectr 2022; 10(2): e0187021.

https://doi.org/10.1128/spectrum.01870-21

10. Çavuşoğlu C, Yaşar-Duman M, Sezai Taşbakan M, Işıkgöz-Taşbakan M, Nurullah Orman M. Evaluation of the performance of QuantiFERON®-TB Gold plus test in active tuberculosis patients. J Clin Tuberc Other Mycobact Dis 2021; 23: 100223.

https://doi.org/10.1016/j.jctube.2021.100223

11. Akbar AA, Islam MN, Rahman M. Comparison of Mantoux test with quantiFERON-TB gold plus assay for detection of tuberculosis infection among chronic kidney disease patients in a tertiary care hospital in Dhaka city. Infection 2021: 24-29.

12. Nolan-Kenney RC, Wang Y, Liu M. Diagnostic Test Basics: A Primer for Neuro-Ophthalmologists. J Neuroophthalmol 2020; 40(4): 445-449. https://doi.org/10.1097/wno.0000000000001149

13. Asai T. COVID-19: accurate interpretation of diagnostic tests—a statistical point of view. J Anesth 2021; 35(3): 328-332.

https://doi.org/10.1007/s00540-020-02875-8

14. Ravi Shankar MS, Aravindan AN, Sohal PM, Kohli HS, Sud K, Gupta KL, et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005; 20(12): 2720-2724.

https://doi.org/10.1093/ndt/gfi141

15. Altamura S, Pietropaoli D, Lombardi F, Del Pinto R, Ferri C. An overview of chronic kidney disease pathophysiology: The impact of gut dysbiosis and oral disease. Biomedicines 2023; 11(11): 3033. https://doi.org/10.3390/biomedicines11113033

16. Zhang H, Li T, Jia Y. Association of estimated glomerular filtration rate with prostate cancer risk in a cross-ethnic population: a Mendelian randomization study. BMC Urology 2024; 24: 18-25. https://doi.org/10.1186/s12894-024-01402-1

17. Oh CE, Ortiz-Brizuela E, Bastos ML, Menzies D. Comparing the diagnostic performance of QuantiFERON-TB Gold Plus to other tests of latent tuberculosis infection: a systematic review and meta-analysis. Clin Infect Dis 2021; 73(5): 1116-1125.

https://doi.org/10.1093/cid/ciaa1822

18. Primaturia C, Reniarti L, Nataprawira HM. Comparison between the Interferon γ Release Assay—QuantiFERON Gold Plus (QFT‐Plus)—and Tuberculin Skin Test (TST) in the Detection of Tuberculosis Infection in Immunocompromised Children. Pulmonary Med 2020;2020(1):7159485.

https://doi.org/10.1155/2020/7159485

19. Yancey JR, Melchert VE. QuantiFERON-TB Gold+ for the diagnosis of Mycobacterium tuberculosis infection. Am Fam Physician 2021; 103(3): 177-188.